Download PDF
Pharmacopsychiatry 2004; 37(1): 26-31
DOI: 10.1055/s-2004-815471
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Combination of Clozapine and Amisulpride in Treatment-Resistant Schizophrenia - Case Reports and Review of the Literature

Mathias Zink1 , Udo Knopf1 , Fritz A. Henn1 , Johannes Thome1
  • 1Central Institute of Mental Health, Mannheim, Germany
Further Information

Publication History

Received: 16. 8. 2002 Revised: 6. 11. 2002

Accepted: 4. 12. 2002

Publication Date:
29 January 2004 (online)

Also available at
    Permissions and Reprints

Background: The clinical outcome of patients suffering from schizophrenic psychoses has been considerably improved by atypical antipsychotics like clozapine and amisulpride. In patients whose symptomatology cannot be ameliorated by monotherapy, it might be necessary to combine two atypical antipsychotics.

While clozapine interacts with a variety of neurotransmitter receptors, amisulpride predominantly binds with high affinity to D3/D2-dopamine receptors. Combination can be considered if a supplementary dopamine-receptor blockade is desired.

Methods: We report on the therapy of 15 patients using a combination regimen of amisulpride and clozapine. Data were collected from patient records. The case reports document previous treatment attempts, describe the reason for the combination therapy, and determine its effect.

Results: Major (six cases) or at least marked (eight cases) improvement of previously treatment-resistant positive and negative symptoms could be achieved by using a mean clozapine dose of 375 mg/day (serum level 0.38 mg/l) and an amisulpride dose of 527 mg/day. Additionally, by reducing the clozapine dose compared to monotherapy by 24 %, a significant reduction of side effects was observed.

Conclusions: The combination of amisulpride with clozapine considerably enriches the therapeutic arsenal in cases of severe schizophrenic psychoses. Additional prospective studies are needed in order to systematically evaluate this new treatment strategy.

References

  • 1 Adler G, Grieshaber S, Faude V, Thebaldi B, Dressing H. Clozapine in patients with chronic schizophrenia: Serum level, EEG and memory performance.  Pharmacopsychiatry. 2002;  35 190-194
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Barnes T R, McEvedy C J, Nelson H E. Management of treatment resistant schizophrenia unresponsive to clozapine.  Br J Psychiat - Suppl. 1996;  31 31-40
    PubMedGoogle Scholar
  • 3 Bennett M R. Monoaminergic synapses and schizophrenia: 45 years of neuroleptics.  J Psychopharmacol. 1998;  12(3) 289-304
    PubMedGoogle Scholar
  • 4 Bleuler E. Handbuch der Psychiatrie. Spezieller Teil. 4. Abteilung. 1911: Dementia praecox oder die Gruppe der Schizophrenien. 
    Google Scholar
  • 5 Bottlender R, Jager M, Hofschuster E, Dobmeier P, Moller H J. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.  Pharmacopsychiatry. 2002;  35(3) 119-121
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Buchanan R W. Clozapine: efficacy and safety.  Schizophr Bull. 1995;  21(4) 579-591
    CrossrefPubMedGoogle Scholar
  • 7 Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications.  Clin Pharmacokinet. 2000;  38(5) 393-414
    PubMedGoogle Scholar
  • 8 Chong S A, Remington G. Clozapine augmentation: safety and efficacy.  Schizophr Bull. 2000;  26(2) 421-440
    PubMedGoogle Scholar
  • 9 Chue P, Welch R, Snaterse M. Combination risperidone and quetiapine therapy in refractory schizophrenia.  Can J Psychiatry - Revue Canadienne de Psychiatrie. 2001;  46(1) 86-87
    PubMedGoogle Scholar
  • 10 Cooke C, de Leon J. Adding other antipsychotics to clozapine.  J Clin Psychiat. 1999;  60(10) 710
    PubMedGoogle Scholar
  • 11 Croissant B, Hermann D, Olbrich R. Saving potential of clozapine due to combination with amisulpride.  Psychopharmakotherapie. 2002;  8(3) 128-130
    PubMedGoogle Scholar
  • 12 de Groot I W, Heck A H, van Harten P N. Addition of risperidone to clozapine therapy in chronically psychotic inpatients.  J Clin Psychiat. 2001;  62(2) 129-130
    PubMedGoogle Scholar
  • 13 Delcker A, Schoon M L, Oczkowski B, Gaertner H J. Amisulpride versus haloperidol in treatment of schizophrenic patients-results of a double-blind study.  Pharmacopsychiatry. 1990;  23(2) 125-130
    PubMedGoogle Scholar
  • 14 Deniker P. The neuroleptics: a historical survey.  Acta Psychiat Scand Suppl. 1990;  358 83-87
    PubMedGoogle Scholar
  • 15 Duval A M, Goldman D. The new drugs (chlorpromazine & reserpine): administrative aspects. 1956.  Psychiat Serv. 2000;  51(3) 327-331
    PubMedGoogle Scholar
  • 16 Freudenreich O, Goff D C. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.  Acta Psychiat Scand. 2002;  106 323-330
    CrossrefPubMedGoogle Scholar
  • 17 Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.  Biol Psychiat. 1997;  42(6) 522-523
    PubMedGoogle Scholar
  • 18 Green A I, Schildkraut J J. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients.  Harv Rev Psychiat. 1995;  3(1) 1-9
    PubMedGoogle Scholar
  • 19 Grohmann R, Koch R, Schmidt L G. Extrapyramidal symptoms in neuroleptic recipients.  Agents Actions - Suppl. 1990;  29 71-82
    PubMedGoogle Scholar
  • 20 Gupta S, Sonnenberg S J, Frank B. Olanzapine augmentation of clozapine.  Ann Clin Psychiat. 1998;  10(3) 113-115
    PubMedGoogle Scholar
  • 21 Hellewell J S. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.  J Clin Psychiat. 1999;  60 Suppl 23 14-19
    PubMedGoogle Scholar
  • 22 Henderson D C, Goff D C. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.  J Clin Psychiat. 1996;  57(9) 395-397
    PubMedGoogle Scholar
  • 23 Horacek J. Novel antipsychotics and extrapyramidal side effects. Theory and reality.  Pharmacopsychiatry. 2000;  33 Suppl 1 34-42
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Koshino Y. Algorithm for treatment-refractory schizophrenia.  Psychiat Clin Neurosci. 1999;  53 Suppl S9S13
    PubMedGoogle Scholar
  • 25 Kraepelin E. Dementia precox and paraphrenia. 8. Edinburgh; E. and S. Livingstone 1919
    Google Scholar
  • 26 Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lemperiere T. et al . Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia.  Neuropsychobiology. 2001;  44(1) 41-46
    PubMedGoogle Scholar
  • 27 Leucht S, Pitschel-Walz G, Engel R R, Kissling W. Amisulpride, an unusual ”atypical” antipsychotic: A meta-Analysis of randomized controlled trials.  Am J Psychiat. 2002;  159 180-190
    CrossrefPubMedGoogle Scholar
  • 28 Mann K, Bartels M, Bauer H, Gaertner H J. Amisulpride - an open clinical study of a new benzamide in schizophrenic patients.  Pharmacopsychiatry. 1984;  17(4) 111-115
    PubMedGoogle Scholar
  • 29 Marsalek M. Tardive drug-induced extrapyramidal syndromes.  Pharmacopsychiatry. 2000;  33 Suppl 1 14-33
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Meltzer H Y. An overview of the mechanism of action of clozapine.  J Clin Psychiat. 1994;  55 Suppl B 7-52
    PubMedGoogle Scholar
  • 31 Meyer J M, Simpson G M. From chlorpromazine to olanzapine: a brief history of antipsychotics.  Psychiat Serv. 1997;  48(9) 1137-1139
    PubMedGoogle Scholar
  • 32 Miller D D. Review and management of clozapine side effects.  J Clin Psychiat. 2000;  61 Suppl 8 14 - 17; discussion 18 -17; discussion 18 - 19
    PubMedGoogle Scholar
  • 33 Moeller H J. Amisulpride: a review of its efficacy in schizophrenia.  Acta Psychiat Scand Suppl. 2000;  400 17-22
    PubMedGoogle Scholar
  • 34 Moore N A. Behavioural pharmacology of the new generation of antipsychotic agents.  Br J Psychiat Suppl. 1999;  38 5-11
    PubMedGoogle Scholar
  • 35 Pantelis C, Barnes T R. Drug strategies and treatment-resistant schizophrenia.  Aust N Z J Psychiat. 1996;  30(1) 20-37
    PubMedGoogle Scholar
  • 36 Pantelis C, Barnes T R. Drug strategies and treatment-resistant schizophrenia.  Aust N Z J Psychiat. 1996;  30(1) 20-37
    PubMedGoogle Scholar
  • 37 Prior T I, Chue P S, Tibbo P, Baker G B. Drug metabolism and atypical antipsychotics.  Eur Neuropsychopharmacol. 1999;  9(4) 301-309
    PubMedGoogle Scholar
  • 38 Raskin S, Katz G, Zislin Z, Knobler H Y, Durst R. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.  Acta Psychiat Scand. 2000;  101(4) 334-336
    PubMedGoogle Scholar
  • 39 Rein W, Coulouvrat C, Dondey-Nouvel L. Safety profile of amisulpride in short- and long-term use.  Acta Psychiat Scand Suppl. 2000;  400 23-27
    PubMedGoogle Scholar
  • 40 Rein W, Turjanski S. Clinical update on amisulpride in deficit schizophrenia.  Int Clin Psychopharmacol. 1997;  12 Suppl 2 S19-27
    PubMedGoogle Scholar
  • 41 Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger D J. et al . Amisulpride: from animal pharmacology to therapeutic action.  Int Clin Psychopharmacol. 1997;  12 Suppl 2 S29-36
    PubMedGoogle Scholar
  • 42 Sethi K D. Movement disorders induced by dopamine blocking agents.  Semin Neurol. 2001;  21(1) 59-68
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Shen W W. A history of antipsychotic drug development.  Compr Psychiat. 1999;  40(6) 407-414
    CrossrefPubMedGoogle Scholar
  • 44 Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P. et al . Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.  Br J Psychiat. 1997;  171 569-573
    Google Scholar
  • 45 Stahl S M. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?.  J Clin Psychiat. 1999;  60(7) 425-426
    PubMedGoogle Scholar
  • 46 Stahl S M. Antipsychotic polypharmacy: evidence based or eminence based?.  Acta Psychiat Scand. 2002;  106 321-322
    PubMedGoogle Scholar
  • 47 Stahl S M. Antipsychotic polypharmacy: squandering precious recources?.  J Clin Psychiat. 2002;  63(2) 93-94
    CrossrefPubMedGoogle Scholar
  • 48 Stephenson C M, Pilowsky L S. Psychopharmacology of olanzapine. A review.  Br J Psychiat Suppl. 1999;  (38) 52-58
    PubMedGoogle Scholar
  • 49 Stern R G, Schmeidler J, Davidson M. Limitations of controlled augmentation trials in schizophrenia.  Biol Psychiat. 1997;  42(2) 138-143
    PubMedGoogle Scholar
  • 50 Stubbs J H, Haw C M, Staley C J, Mountjoy C Q. Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine.  Acta Psychiat Scand. 2000;  102(5) 390 - 393; discussion 393 -393; discussion 393 - 394
    PubMedGoogle Scholar
  • 51 Taylor C G, Flynn S W, Altman S, Ehmann T, MacEwan G W, Honer W G. An open trial of risperidone augmentation of partial response to clozapine.  Schizophr Res. 2001;  48(1) 155-158
    CrossrefPubMedGoogle Scholar
  • 52 Wirshing D A. Adverse effects of atypical antipsychotics.  J Clin Psychiat. 2001;  62 Suppl 21 7-10
    PubMedGoogle Scholar
  • 53 Wirshing D A, Wirsshing W C, Kysar L, Berisford M A, Goldstein D, Pashdag J. et al . Novel antipsychotics: comparison of weight gain liabilities.  J Clin Psychiat. 1999;  60 358-363
    CrossrefPubMedGoogle Scholar
  • 54 Young C R, Bowers M B Jr, Mazure C M. Management of the adverse effects of clozapine.  Schizophr Bull. 1998;  24 381-390
    PubMedGoogle Scholar
  • 55 Young C R, Longhurst J G, Bowers M B Jr, Mazure C M. The expanding indications for clozapine.  Exp Clin Psychopharmacol. 1997;  5(3) 216-234
    CrossrefPubMedGoogle Scholar

Dr. med. Mathias Zink

Central Institute of Mental Health

P.O. Box: 12 21 20

D-68072 Mannheim

Germany

Fax: +49-621-23429

Phone: +49-621-1703-0

Email: zink@kv.zi-mannheim.de

      >